| Name | Title | Contact Details |
|---|
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
Pediatrics Plus is a specialized pediatric healthcare provider committed to helping your child succeed in all stages of life through therapy and education.
Amalgam Rx develops digital therapies that empower patients with chronic diseases to achieve better outcomes
Nucryst Pharmaceuticals Corp. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The DENT Neurologic Institute is among the largest, most comprehensive neurology practices in the United States. We are focused on providing superior clinical care, advanced diagnostic services, clinical research, and education.